Aspergillus osteomyelitis in a child who has p67-phox-deficient chronic granulomatous disease.

Here we describe Aspergillus osteomyelitis of the tibia in a 9-year-old boy who has an autosomal recessive form of chronic granulomatous disease (CGD). The patient showed a p67-phagocyte oxidase (phox) deficiency, which is rare type of CGD in Japan. The initial treatment which consisted of surgical debridement and antibiotic therapy with amphotericin B (AMPH), did not control the infection. Aspergillus fumigatus (A. fumigatus) pure isolated from drainage fluid and necrotic bone tissue demonstrated less susceptible to antifungal agents, including AMPH, fluconazole and flucytosine. Recombinant interferon gamma was then administrated, and it was effective in controlling the course of severe invasive aspergillosis. This report indicates the use of interferon gamma might be helpful in control for Aspergillus osteomyelitis of the tibia in a child with CGD demonstrated p67-phox deficiency refractory to conventional therapy with AMPH.
AuthorsN Tsumura, Y Akasu, H Yamane, S Ikezawa, T Hirata, K Oda, Y Sakata, M Shirahama, A Inoue, H Kato
JournalThe Kurume medical journal (Kurume Med J) Vol. 46 Issue 1 Pg. 87-90 ( 1999) ISSN: 0023-5679 [Print] JAPAN
PMID10319618 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Phosphoproteins
  • Recombinant Proteins
  • neutrophil cytosol factor 67K
  • Amphotericin B
  • Interferon-gamma
  • Amphotericin B (therapeutic use)
  • Aspergillosis (therapy)
  • Child
  • Granulomatous Disease, Chronic (therapy)
  • Humans
  • Interferon-gamma (therapeutic use)
  • Male
  • Osteomyelitis (therapy)
  • Phosphoproteins (deficiency)
  • Recombinant Proteins
  • Tibia

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: